RT Journal Article SR Electronic T1 INTREPID: single- versus multiple-inhaler triple therapy for COPD in usual clinical practice JF ERJ Open Research JO erjor FD European Respiratory Society SP 00950-2020 DO 10.1183/23120541.00950-2020 VO 7 IS 2 A1 David M.G. Halpin A1 Sally Worsley A1 Afisi S. Ismaila A1 Kai-Michael Beeh A1 Dawn Midwinter A1 Janwillem W.H. Kocks A1 Elaine Irving A1 Jose M. Marin A1 Neil Martin A1 Maggie Tabberer A1 Neil G. Snowise A1 Chris Compton YR 2021 UL http://openres.ersjournals.com/content/7/2/00950-2020.abstract AB Introduction Real-world trial data comparing single- with multiple-inhaler triple therapy (MITT) in COPD patients are currently lacking. The effectiveness of once-daily single-inhaler fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) and MITT were compared in usual clinical care.Methods INTREPID was a multicentre, randomised, open-label, phase IV effectiveness study comparing FF/UMEC/VI 100/62.5/25 µg via the ELLIPTA inhaler with a clinician's choice of any approved non-ELLIPTA MITT in usual COPD clinical practice in five European countries. Primary end-point was proportion of COPD Assessment Test (CAT) responders (≥2-unit decrease in CAT score from baseline) at week 24. Secondary end-points in a subpopulation included change from baseline in forced expiratory volume in 1 s (FEV1) and percentage of patients making at least one critical error in inhalation technique at week 24. Safety was also assessed.Results 3092 patients were included (FF/UMEC/VI n=1545; MITT n=1547). The proportion of CAT responders at week 24 was significantly greater with FF/UMEC/VI versus non-ELLIPTA MITT (OR 1.31, 95% CI 1.13–1.51; p<0.001) and mean change from baseline in FEV1 was significantly greater with FF/UMEC/VI (77 mL versus 28 mL; treatment difference 50 mL, 95% CI 26–73 mL; p<0.001). The percentage of patients with at least one critical error in inhalation technique was low in both groups (FF/UMEC/VI 6%; non-ELLIPTA MITT 3%). Safety profiles, including incidence of pneumonia serious adverse events, were similar between treatments.Conclusions In a usual clinical care setting, treatment with once-daily single-inhaler FF/UMEC/VI resulted in significantly more patients gaining health status improvement and greater lung function improvement versus non-ELLIPTA MITT.Once-daily single-inhaler treatment with FF/UMEC/VI results in greater improvements in health status and lung function compared with non-ELLIPTA multiple-inhaler triple therapy in patients with COPD in a usual clinical practice setting https://bit.ly/2PHXNwU